Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs.
Brenner
Steven R
SR
D001928:Brain Diseases, Metabolic / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D002908:Chronic Disease / Q000188:drug therapy / Q000517:prevention & control; D004272:DNA, Mitochondrial / Q000235:genetics*; D018450:Disease Progression; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006239:Haplotypes; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D028361:Mitochondrial Diseases / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D012256:Riboflavin / Q000627:therapeutic use*; D008063:Thioctic Acid / Q000494:pharmacology / Q000627:therapeutic use; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D014803:Vitamin B Complex / Q000627:therapeutic use
D004272:DNA, Mitochondrial; D014803:Vitamin B Complex; D014451:Ubiquinone; D008063:Thioctic Acid; C024989:coenzyme Q10; D012256:Riboflavin